NASDAQ:DCPH - Deciphera Pharmaceuticals Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $70.50
Forecasted Upside: 88.70 %
Number of Analysts: 7
Breakdown:
0 Sell Ratings
1 Hold Ratings
6 Buy Ratings
0 Strong Buy Ratings

^$37.36 As of 06/18/2021 01:00 AM ET

▲ +0.52 (1.41%)

1 month | 3 months | 12 months

Get New Deciphera Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for DCPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DCPH

^$70.50

▲ +88.70% Upside Potential

This price target is based on 7 analysts offering 12 month price targets for Deciphera Pharmaceuticals in the last 3 months. The average price target is $70.50, with a high forecast of $78.00 and a low forecast of $60.00. The average price target represents a 88.70% upside from the last price of $37.36.

Buy

The current consensus among 7 contributing investment analysts is to buy stock in Deciphera Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
10 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

12/25/2019

0 strong buy ratings
13 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/24/2020

0 strong buy ratings
13 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

6/22/2020

0 strong buy ratings
10 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

9/20/2020

0 strong buy ratings
11 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

12/19/2020

0 strong buy ratings
6 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

3/19/2021

0 strong buy ratings
8 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

5/18/2021

0 strong buy ratings
6 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

6/17/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/5/2021	HC Wainwright	Lower Price Target	Buy	$80.00 ➝ $75.00	High
5/5/2021	Barclays	Lower Price Target	Overweight	$70.00 ➝ $65.00	High
5/5/2021	Piper Sandler	Lower Price Target	Overweight	$75.00 ➝ $60.00	High
3/30/2021	Credit Suisse Group	Initiated Coverage	Outperform	$78.00	High
2/10/2021	Barclays	Lower Price Target	Overweight	$85.00 ➝ $70.00	Low
2/10/2021	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$70.00	Low
12/2/2020	Stifel Nicolaus	Initiated Coverage	Buy	$75.00	Medium
11/12/2020	SVB Leerink	Boost Price Target	Market Perform	$58.00 ➝ $70.00	Low
9/14/2020	SVB Leerink	Boost Price Target	Market Perform	$54.00 ➝ $58.00	Medium
9/14/2020	JPMorgan Chase & Co.	Initiated Coverage	Neutral		High
8/5/2020	SVB Leerink	Lower Price Target	Market Perform	$55.00 ➝ $54.00	Low
6/12/2020	Guggenheim	Reiterated Rating	Buy	$70.00	High
5/18/2020	SunTrust Banks	Boost Price Target	Buy	$82.00 ➝ $91.00	Medium
5/18/2020	Barclays	Reiterated Rating	Buy	$80.00 ➝ $85.00	Medium
5/7/2020	Nomura Instinet	Downgrade	Buy ➝ Neutral	$84.00 ➝ $60.00	Low
5/6/2020	Nomura	Downgrade	Buy ➝ Neutral	$84.00 ➝ $60.00	Low
5/6/2020	JPMorgan Chase & Co.	Lower Price Target	Overweight	$50.00 ➝ $49.00	High
5/6/2020	HC Wainwright	Boost Price Target	Buy	$60.00 ➝ $80.00	High
4/29/2020	SunTrust Banks	Boost Price Target	Buy	$77.00 ➝ $82.00	Medium
4/29/2020	SVB Leerink	Boost Price Target	Hold	$50.00 ➝ $55.00	Medium
3/4/2020	Barclays	Initiated Coverage	Overweight	$70.00	High
1/22/2020	Piper Sandler	Reiterated Rating	Buy	$75.00	Low
1/21/2020	Nomura Securities	Boost Price Target	Buy	$57.00 ➝ $84.00	Low
1/15/2020	JMP Securities	Reiterated Rating	Buy	$70.00	Low
1/10/2020	SunTrust Banks	Initiated Coverage	Buy	$77.00	Low
12/20/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$55.00 ➝ $75.00	Low
12/20/2019	Jefferies Financial Group	Boost Price Target	Buy	$53.00 ➝ $77.00	Medium
11/5/2019	JMP Securities	Boost Price Target	Outperform ➝ Market Outperform	$45.00 ➝ $54.00	Low
10/29/2019	SVB Leerink	Upgrade	Underperform ➝ Market Perform	$29.00 ➝ $34.00	Medium
10/22/2019	JMP Securities	Initiated Coverage	Outperform		Low
10/3/2019	HC Wainwright	Initiated Coverage	Buy	$60.00	High
9/30/2019	Piper Jaffray Companies	Set Price Target	Buy	$55.00	High
9/30/2019	Jefferies Financial Group	Initiated Coverage	Buy	$47.00	High
8/14/2019	SunTrust Banks	Boost Price Target	Positive ➝ Buy	$60.00	Low
8/14/2019	SVB Leerink	Reiterated Rating	Underperform ➝ Positive	$20.00 ➝ $29.00	High
8/14/2019	Cantor Fitzgerald	Boost Price Target	Overweight	$43.00 ➝ $55.00	High
8/14/2019	Canaccord Genuity	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $65.00	Medium
8/13/2019	Guggenheim	Boost Price Target	Buy	$44.00 ➝ $66.00	High
7/18/2019	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy ➝ Buy	$42.00	Low
6/3/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$50.00 ➝ $55.00	High
3/15/2019	Canaccord Genuity	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $50.00	High
1/1/2019	B. Riley	Downgrade	Buy ➝ Neutral		High
12/31/2018	B. Riley	Initiated Coverage	Neutral ➝ Buy	$27.00 ➝ $34.00	High
12/20/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$53.00	Medium
11/16/2018	SVB Leerink	Lower Price Target	Underperform	$28.00 ➝ $20.00	Medium
10/3/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$53.00	Medium
9/24/2018	SVB Leerink	Initiated Coverage	Underperform ➝ Underperform	$28.00	Low
9/17/2018	Guggenheim	Initiated Coverage	Buy		High
9/6/2018	Cantor Fitzgerald	Initiated Coverage	Buy	$53.00	High
8/29/2018	Raymond James	Initiated Coverage	Outperform ➝ Outperform	$47.00	Medium
8/22/2018	Cantor Fitzgerald	Initiated Coverage	Overweight	$53.00	Medium
8/13/2018	Canaccord Genuity	Set Price Target	Buy	$55.00	Low
8/7/2018	Canaccord Genuity	Initiated Coverage	Buy	$55.00	Low
7/5/2018	SunTrust Banks	Initiated Coverage	Buy		High
6/19/2018	JMP Securities	Boost Price Target	Outperform	$65.00	Low
6/19/2018	B. Riley	Downgrade	Buy ➝ Neutral	$43.00	Medium
6/12/2018	Piper Jaffray Companies	Boost Price Target	Overweight	$50.00	Low
6/4/2018	JPMorgan Chase & Co.	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $33.00	High
5/9/2018	B. Riley	Lower Price Target	Buy ➝ Buy	$52.00 ➝ $43.00	High
2/16/2018	B. Riley	Initiated Coverage	Buy ➝ Buy	$43.00	High
10/23/2017	Nomura Securities	Initiated Coverage	Buy ➝ Buy	$57.00	N/A
10/23/2017	Piper Jaffray Companies	Initiated Coverage	Overweight ➝ Overweight	$35.00	N/A
10/23/2017	Nomura Instinet	Initiated Coverage	Buy	$57.00	N/A
10/23/2017	JMP Securities	Initiated Coverage	Mkt Outperform ➝ Outperform	$38.00	N/A
10/23/2017	JPMorgan Chase & Co.	Initiated Coverage	Overweight ➝ Overweight	$30.00	N/A

(Data available from 6/18/2016 forward)

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase 1b/2 clinical trial to treat metastatic solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, it is developing DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. The company serves in the United States and Europe. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $37.36

$35.91

$38.02

50 Day Range

MA: $38.22

$32.73

$47.95

52 Week Range

Now: $37.36

$31.77

$68.40

Volume

1,001,085 shs

Average Volume

447,809 shs

Market Capitalization

$2.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51

Frequently Asked Questions

What sell-side analysts currently cover shares of Deciphera Pharmaceuticals?

The following Wall Street research analysts have issued reports on Deciphera Pharmaceuticals in the last year: Barclays PLC, Credit Suisse Group AG, HC Wainwright, JPMorgan Chase & Co., Piper Sandler, Stifel Nicolaus, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for DCPH.

What is the current price target for Deciphera Pharmaceuticals?

6 Wall Street analysts have set twelve-month price targets for Deciphera Pharmaceuticals in the last year. Their average twelve-month price target is $70.50, suggesting a possible upside of 88.7%. Credit Suisse Group AG has the highest price target set, predicting DCPH will reach $78.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $60.00 for Deciphera Pharmaceuticals in the next year.
View the latest price targets for DCPH.

What is the current consensus analyst rating for Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DCPH will outperform the market and that investors should add to their positions of Deciphera Pharmaceuticals.
View the latest ratings for DCPH.

What other companies compete with Deciphera Pharmaceuticals?

Other companies that are similar to Deciphera Pharmaceuticals include Mirati Therapeutics, United Therapeutics, Ascendis Pharma A/S, Evotec, Ultragenyx Pharmaceutical, Sarepta Therapeutics, Biohaven Pharmaceutical, Perrigo, Ionis Pharmaceuticals, I-Mab, TG Therapeutics, Schrödinger, Legend Biotech, Reata Pharmaceuticals and Allakos.

How do I contact Deciphera Pharmaceuticals' investor relations team?

Deciphera Pharmaceuticals' physical mailing address is 200 SMITH STREET, Waltham MA, 02451. The company's listed phone number is (781) 209-6400 and its investor relations email address is [email protected] The official website for Deciphera Pharmaceuticals is www.deciphera.com.